Endothelial dysfunction is a determinant of chronic vascular diabetic complications. Diabetic nephropathy (DN) is characterized by defects in glomerular capillaries, resulting in altered angiogenesis and increased vascular permeability and albuminuria. Neurite Outgrowth Inhibitor (Nogo)-B and its soluble form (sNogo-B) have been implicated in vascular remodelling. Both Nogo-B (at the cellular level) and sNogo-B (systemically) bind to NgBR receptor, expressed in endothelial cells, and promote vascular integrity. Nogo-B is expressed in glomerular endothelial cells and podocytes and is downregulated in experimental model of DN, and in patients with diabetes. Our aims were to investigate, in experimental models of DN, whether overexpression of sNogo-B: i) ameliorates altered angiogenesis in vitro; and ii) prevents diabetic glomerulopathy in vivo. METHODS: Serum was obtained from patients with type-1 diabetes (T1DM) with (DN+) or without DN (DN-); the patients with T1DM/DN+ having had a history of albuminuria. Angiogenesis was conducted with human umbilical vein endothelial cells (HUVEC) on Matrigel, in the presence of patients' sera (4%vol/vol), and tube formation quantified after 24h with image analysis. sNogo-B overexpression was achieved with adenoviral vector. Eight to ten weeks-old male DBA/2J mice were made diabetic (streptozotocin/low-dose), and administered (12-14 week-old) an adeno-associated viral vector (AAV) expressing sNogoB or a control vector. Animals were divided into four groups: non-diabetic and diabetic mice treated with either control or sNogoB AAV. Mice were followed until 12-14 weeks of diabetes. Blood pressure was assessed with tail-cuff and glomerular structure by electron microscopy. Plasma/cells' media sNogo-B levels were analysed by ELISA, full-length Nogo-B, Akt and Akt phosphorylation with immunoblotting in kidney cortex lysate, albuminuria by fluorescence. RESULTS: HUVEC cultured in T1DM/DN+ sera displayed a 50% reduction in tube formation when compared to cells cultured in T1DM/DN-sera (p=0.05). sNogo-B overexpression corrected the impaired tube formation observed in cells incubated with T1DM/DN+ sera (p<0.05). Nogo-B was downregulated in HUVEC incubated with T1DM/DN+ sera and sNogo-B overexpression restored it to control levels (p=0.01). Diabetic mice had a significantly raised albuminuria that was ameliorated by overexpression of sNogo-B (p<0.05). Blood pressure tended to be higher in diabetic mice but this was not affected by sNogo-B overexpression. We observed an increase in mesangial expansion in diabetic mice, which was ameliorated in sNogo-B overexpressing diabetic mice (p<0.05). In kidney cortex lysates, sNogo-B overexpression prevented the diabetes-mediated full-length Nogo-B downregulation (p=0.02), and blunted diabetesmediated Akt ser phosphorylation (p=0.01). Total Akt protein levels were downregulated in diabetes (p<0.01), but not affected by sNogo-B overexpression. CONCLUSIONS: Overexpression of sNogo-B ameliorates diabetes-induced albuminuria likely by preventing the diabetes-mediated full-length Nogo-B downregulation which seems to reflect an improved angiogenesis. Studies are ongoing to fully characterise the potential protective role of sNogo-B in DN.
INTRODUCTION AND AIMS:
Endothelial dysfunction is a determinant of chronic vascular diabetic complications. Diabetic nephropathy (DN) is characterized by defects in glomerular capillaries, resulting in altered angiogenesis and increased vascular permeability and albuminuria. Neurite Outgrowth Inhibitor (Nogo)-B and its soluble form (sNogo-B) have been implicated in vascular remodelling. Both Nogo-B (at the cellular level) and sNogo-B (systemically) bind to NgBR receptor, expressed in endothelial cells, and promote vascular integrity. Nogo-B is expressed in glomerular endothelial cells and podocytes and is downregulated in experimental model of DN, and in patients with diabetes. Our aims were to investigate, in experimental models of DN, whether overexpression of sNogo-B: i) ameliorates altered angiogenesis in vitro; and ii) prevents diabetic glomerulopathy in vivo. METHODS: Serum was obtained from patients with type-1 diabetes (T1DM) with (DN+) or without DN (DN-); the patients with T1DM/DN+ having had a history of albuminuria. Angiogenesis was conducted with human umbilical vein endothelial cells (HUVEC) on Matrigel, in the presence of patients' sera (4%vol/vol), and tube formation quantified after 24h with image analysis. sNogo-B overexpression was achieved with adenoviral vector. Eight to ten weeks-old male DBA/2J mice were made diabetic (streptozotocin/low-dose), and administered (12-14 week-old) an adeno-associated viral vector (AAV) expressing sNogoB or a control vector. Animals were divided into four groups: non-diabetic and diabetic mice treated with either control or sNogoB AAV. Mice were followed until 12-14 weeks of diabetes. Blood pressure was assessed with tail-cuff and glomerular structure by electron microscopy. Plasma/cells' media sNogo-B levels were analysed by ELISA, full-length Nogo-B, Akt and Akt phosphorylation with immunoblotting in kidney cortex lysate, albuminuria by fluorescence. RESULTS: HUVEC cultured in T1DM/DN+ sera displayed a 50% reduction in tube formation when compared to cells cultured in T1DM/DN-sera (p=0.05). sNogo-B overexpression corrected the impaired tube formation observed in cells incubated with T1DM/DN+ sera (p<0.05). Nogo-B was downregulated in HUVEC incubated with T1DM/DN+ sera and sNogo-B overexpression restored it to control levels (p=0.01). Diabetic mice had a significantly raised albuminuria that was ameliorated by overexpression of sNogo-B (p<0.05). Blood pressure tended to be higher in diabetic mice but this was not affected by sNogo-B overexpression. We observed an increase in mesangial expansion in diabetic mice, which was ameliorated in sNogo-B overexpressing diabetic mice (p<0.05). In kidney cortex lysates, sNogo-B overexpression prevented the diabetes-mediated full-length Nogo-B downregulation (p=0.02), and blunted diabetesmediated Akt ser phosphorylation (p=0.01). Total Akt protein levels were downregulated in diabetes (p<0.01), but not affected by sNogo-B overexpression. CONCLUSIONS: Overexpression of sNogo-B ameliorates diabetes-induced albuminuria likely by preventing the diabetes-mediated full-length Nogo-B downregulation which seems to reflect an improved angiogenesis. Studies are ongoing to fully characterise the potential protective role of sNogo-B in DN. (DN) is a chronic diabetic complication and the primary cause of end stage renal disease. Our group discovered that urine of DN patients (pts) is enriched in free ubiquitin and that an accumulation of lysine63-ubiquitinated (K63Ub) proteins at tubular level is involved in epithelial-tomesenchymal transition (EMT), driving the progression of kidney fibrosis in DN. We also identified a set of miRNAs differentially expressed in kidneys of DN pts. The aim of this study was to identify miRNAs involved in regulating the expression of K63Ub proteins and assess their potential as diagnostic biomarkers for kidney fibrosis in DN. METHODS: Total RNA was extracted from cell-free urine of 15 biopsy-proven DN pts with type 2 diabetes (T2D), 5 T2D pts with biopsy-proven membranous nephropathy (MN), 4 T2D pts with biopsy-proven focal segmental glomerulosclerosis (FSGF), 18 T2D pts with microalbuminuria, 17 T2D patients with normo-albuminuria, 15 nondiabetic pts with biopsy-proven MN, 7 non-diabetic pts with biopsy-proven FSGS, 8 healthy volunteers. miRNAs expression was assessed by qPCR. RESULTS: Among miRNAs previously identified by microarray analysis as deregulated in the kidney of DN, we found that 9 were deregulated in urine of DN pts (FC >1.5, p<0.05) compared to healthy volunteers, T2D-MN and T2D-FSGS. Next, by in silico analysis we selected 2 of these miRNAs showing a predicted interaction with UBE2V1, an ubiquitin-conjugating E2 enzyme variant that mediates the formation of K63Ub chains. Both miRNAs were tested by qPCR on total RNA derived from kidney biopsies and found downregulated in DN vs T2D-MN pts (p<0.04 and p<0.01) as well as in urine of DN pts compared to all the other categories (p<0.03). One miRNA, conserved among species, was further validated in vivo in renal tissue of streptozotocininduced diabetic mice with renal damage (DBA2J/STZ) (p<0.05 vs DBA2J). The down-regulation of both miRNAs in vivo, at tubular level, was also detected by in situ hybridization (p<0.05). Given the role of these miRNAs in EMT, we tested their diagnostic potential by matching their urinary expression with the degree of fibrosis shown at the tissue level by Masson's trichrome staining. Interestingly, urinary levels of one of these miRNAs was able to discriminate between different degrees of renal fibrosis in DN pts (p=0.03). CONCLUSIONS: In conclusion, we confirmed the role of ubiquitination as a key pathogenic mechanism in the progression of kidney damage and we identified two regulatory miRNAs as potential diagnostic biomarkers of tubular-interstitial fibrosis in DN.
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